Hepatocellular Carcinoma

Duration Associated with Survival in Advanced Hepatocellular Carcinoma Treated with Sorafenib

Duration Associated with Survival in Advanced Hepatocellular Carcinoma Treated with Sorafenib

Duration of stability linked with overall survival in advanced hepatocellular carcinoma treated with the tyrosine kinase inhibitor sorafenib.

Vegetables, Not Fruit, Reduce Risk of Hepatocellular Carcinoma

Vegetables, Not Fruit, Reduce Risk of Hepatocellular Carcinoma

Reduction in summary relative risk of hepatocellular carcinoma with increased vegetable, but not fruit, intake.

Everolimus Use in Sorafenib-Refractory Hepatocellular Carcinoma

Everolimus Use in Sorafenib-Refractory Hepatocellular Carcinoma

By

Researchers continue to search for a molecular pathway or biomarker to improve treatment options for patients with sorafenib-refractory HCC.

ENMD-2076 Receives Orphan Drug Designation for HCC

ENMD-2076 Receives Orphan Drug Designation for HCC

CASI Pharmaceuticals announced that the FDA has granted Orphan Drug designation to ENMD-2076 for the treatment of hepatocellular carcinoma.

Everolimus Didn't Improve Survival in Advanced HCC

Everolimus Didn't Improve Survival in Advanced HCC

Researchers found no survival difference found between patients receiving everolimus or placebo.

Benefits of HCC Screening Remain Unclear

Benefits of HCC Screening Remain Unclear

The benefits of hepatocellular carcinoma screening are unclear in patients with chronic liver disease.

Vitamin D May Lower Liver Cancer Risk

Vitamin D May Lower Liver Cancer Risk

A new study in Western Europeans shows that vitamin D lowers the risk of developing hepatocellular carcinoma.

Antivirals May Protect HBV Patients from Liver Cancer

Antivirals May Protect HBV Patients from Liver Cancer

Researchers have found that antiviral therapy may be successful in preventing hepatitis B virus from developing into the most common form of liver cancer, hepatocellular carcinoma.

AFP Detects Liver Cancer in Patients Without HCV

AFP Detects Liver Cancer in Patients Without HCV

Measurement of α-fetoprotein detects hepatocellular carcinoma most accurately in patients without hepatitis C virus infection.

Updated Results Announced for ThermoDox Use for HCC

Updated Results Announced for ThermoDox Use for HCC

Celsion announced updated results from its HEAT Study post-hoc analysis which examined the use of ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, in combination with radiofrequency ablation (RFA) for the treatment of hepatocellular carcinoma (HCC).

Lipiodol Earns FDA Approval for Tumor Imaging in HCC

Lipiodol Earns FDA Approval for Tumor Imaging in HCC

By

The FDA has approved Guerbet's Lipiodol (ethiozed oil) injection for imaging of hepatocellular carcinoma tumors

Drinking More Coffee May Lower Liver Cancer Risk

Drinking More Coffee May Lower Liver Cancer Risk

Increased coffee consumption may reduce hepatocellular carcinoma risk across ethnicities, according to a study presented at the AACR Annual Meeting.

Novel Kinase Inhibitor Shows Efficacy in Patients with Advanced HCC Tumors Overexpressing AFP

Novel Kinase Inhibitor Shows Efficacy in Patients with Advanced HCC Tumors Overexpressing AFP

By

LY2157299 monohydrate showed promising efficacy results in patients with advanced HCC tumors overexpressing AFP.

Everolimus Failed to Improve Survival in Advanced HCC

Everolimus Failed to Improve Survival in Advanced HCC

By

Data indicate that everolimus did not improve overall survival in patients with advanced HCC following sorafenib failure.

Gastrointestinal Toxicity of Sorafenib

Gastrointestinal Toxicity of Sorafenib

By

Sorafenib can be an effective treatment for a variety of cancers, but its use can come with significant GI side effects.

Anti-CLTA4 Immunotherapy Achieves Antitumor Effects in Small Study of Hepatitis C-Related Hepatocellular Carcinoma

Anti-CLTA4 Immunotherapy Achieves Antitumor Effects in Small Study of Hepatitis C-Related Hepatocellular Carcinoma

By

Immunotherapy targeting the CLTA4 protein in HCV-related HCC demonstrated modest extended survival in a disease that has a high mortality rate.

Targeting Vascular Endothelial Growth Factor in Treatment of Hepatocellular Carcinoma

Targeting Vascular Endothelial Growth Factor in Treatment of Hepatocellular Carcinoma

By

Despite HCC having a poor prognosis and high mortality, systemic antiangiogenesis therapies offer some hope to patients.

Creating a Multidisciplinary Hepatocellular Carcinoma Clinic Improves Survival

By

Forming a multidisciplinary clinic for patients with HCC resulted in improved survival, likely due to more streamlined care and earlier diagnosis, found research presented at SSO 2013.

Survival After Radiofrequency Ablation Might be 'Comparable' to Resection for Liver Cancer

By

Radiofrequency ablation might offer comparable survival rates when compared with liver surgery for patients with hepatocellular carcinoma.

Aspirin Use Associated with Lower Liver Cancer Risk and Chronic Liver Disease Mortality Rates

By

Aspirin use, but not the use of other nonsteroidal anti-inflammatory drugs (NSAIDs), is associated with a reduced risk of developing hepatocellular carcinoma.

RSNA: DEB TACE Viable Treatment Option for Advanced Unresectable HCC

By

Patients with advanced unresectable hepatocellular carcinoma have a higher median overall survival when treated with drug eluting bead transarterial chemoembolization.

DEBs and the Treatment of Unresectable HCC

DEBs and the Treatment of Unresectable HCC

By

Drug-eluting beads are a new type of drug delivery system that may be able to decrease side effects and localize chemotherapy treatment in HCC patients.

Clinical Trial for Novel Liver Cancer Drug Begins

By

The first patient has been treated in a phase 2 clinical trial of intravenous delivery JX-594 in patients with advanced hepatocellular carcinoma.

First-Line Brivanib Fails Against Sorafenib on OS End Point in HCC

By

In a randomized phase 3 trial, first-line brivanib did not meet its primary overall survival end point in patients with hapatocellular carcinoma.

Patients with Alcoholic Cirrhosis at Low Risk for HCC; Surveillance Not Warranted

By

A cohort study of Danish patients with alcoholic cirrhosis suggests that because they are at low risk for hepatocellular carcinoma (HCC), "surveillance would be expected to have a minimal effect on mortality and is unlikely to be cost effective,"

Family History of Liver Cancer, HBV/HCV Infection Increase Risk of HCC

By

The investigators sought to understand the relationships between familial clustering of hepatocellular carcinoma (HCC), family history of liver cancer and the incidence of hepatitis.

Childhood Obesity Increases Risk of Adult HCC

By

Danish researchers have established a link between childhood obesity and hepatocellular carcinoma (HCC) in adults.

SIRT-Sorafenib Combination Shows Efficacy in Patients with HCC

Loco-regional therapy with selective internal radiation therapy (SIRT) and sorafenib demonstrated good efficacy in patients with advanced hepatocellular carcinoma (HCC), especially those in Barcelona Clinic Liver Criteria (BCLC) stage B.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs